133 related articles for article (PubMed ID: 2149807)
1. Changes in coagulation and fibrinolysis variables during use of two oral contraceptives containing the same dose of ethinyl estradiol and either gestodene or desogestrel.
Gevers Leuven JA; Kluft C; Dersjant-Roorda MC; Harthoorn-Lasthuizen EJ; Peters FP; Bernsen MJ; Helmerhorst FM
Adv Contracept; 1990 Dec; 6 Suppl():69-73. PubMed ID: 2149807
[No Abstract] [Full Text] [Related]
2. Blood coagulation with a combination pill containing gestodene and ethinyl estradiol.
Bonnar J; Daly L; Carroll E
Int J Fertil; 1987; 32 Suppl():21-8. PubMed ID: 2906344
[TBL] [Abstract][Full Text] [Related]
3. Comparative studies of 30 micrograms ethinyl estradiol combined with gestodene and desogestrel on blood coagulation, fibrinolysis, and platelets.
Daly L; Bonnar J
Am J Obstet Gynecol; 1990 Jul; 163(1 Pt 2):430-7. PubMed ID: 2142580
[TBL] [Abstract][Full Text] [Related]
4. Effects of two oral contraceptives, containing 30 or 20 microg of ethinyl estradiol in combination with gestodene, on blood coagulation and fibrinolysis in Brazilian women.
Ferreira AC; Montes MB; Franceschini SA; Toloi MR
Int J Fertil Womens Med; 2001; 46(5):265-70. PubMed ID: 11720199
[TBL] [Abstract][Full Text] [Related]
5. Oral contraceptives and blood coagulation.
Bonnar J; Sabra AM
J Reprod Med; 1986 Jun; 31(6 Suppl):551-6. PubMed ID: 2941571
[TBL] [Abstract][Full Text] [Related]
6. Effects of monophasic low-dose oral contraceptives on fibrin formation and resolution in young women.
Petersen KR; Sidelmann J; Skouby SO; Jespersen J
Am J Obstet Gynecol; 1993 Jan; 168(1 Pt 1):32-8. PubMed ID: 8420344
[TBL] [Abstract][Full Text] [Related]
7. [Effects of oral estrogen-progestin contraceptives on blood coagulation and assessment of the risk of thromboembolism].
Surico N; Porcelli A; Petrelli P; Amedeo M; Crivello T; Ferraris G
Minerva Ginecol; 1988 Sep; 40(9):559-62. PubMed ID: 2975773
[No Abstract] [Full Text] [Related]
8. Effect of oral contraceptives on markers of hyperandrogenism and SHBG in women with polycystic ovary syndrome.
De Leo V; Di Sabatino A; Musacchio MC; Morgante G; Scolaro V; Cianci A; Petraglia F
Contraception; 2010 Sep; 82(3):276-80. PubMed ID: 20705157
[TBL] [Abstract][Full Text] [Related]
9. Sex hormone binding globulin, cortisol binding globulin, thyroxine binding globulin, ceruloplasmin: changes in treatment with two oral contraceptives low in oestrogen.
Sobbrio GA; Granata A; Granese D; D'Arrigo F; Panacea A; Nicita R; Pullè C; Trimarchi F
Clin Exp Obstet Gynecol; 1991; 18(1):43-5. PubMed ID: 1829029
[TBL] [Abstract][Full Text] [Related]
10. Effects of desogestrel and gestodene in low-dose oral contraceptive combinations on lipid and lipoprotein status. A randomized prospective study.
Granata A; Sobbrio GA; D'Arrigo F; Barillari M; Curasì MP; Egitto M; Trimarchi F; Granese D; Pullè C
Acta Eur Fertil; 1990; 21(3):143-6. PubMed ID: 2149913
[TBL] [Abstract][Full Text] [Related]
11. [The combined effect of an ethinylestradiol/desogestrel contraceptive combination on blood lipids and parameters of liver function and coagulation].
Massafra C; Capitani S; Bernabei A; Scillone L
Rev Fr Gynecol Obstet; 1988 Apr; 83(4):251-5. PubMed ID: 2969134
[TBL] [Abstract][Full Text] [Related]
12. Comparative evaluation of the androgenicity of four low-dose, fixed-combination oral contraceptives.
Coenen CM; Thomas CM; Borm GF; Rolland R
Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():92-7. PubMed ID: 8574256
[TBL] [Abstract][Full Text] [Related]
13. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives.
Quehenberger P; Loner U; Kapiotis S; Handler S; Schneider B; Huber J; Speiser W
Thromb Haemost; 1996 Nov; 76(5):729-34. PubMed ID: 8950781
[TBL] [Abstract][Full Text] [Related]
14. Progestagen-dependent effect on some plasma proteins during oral contraception.
Liukko P; Erkkola R; Bergink EW
Gynecol Obstet Invest; 1988; 25(2):118-22. PubMed ID: 2967233
[TBL] [Abstract][Full Text] [Related]
15. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
Teichmann A
Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
[TBL] [Abstract][Full Text] [Related]
16. Development of an oral contraceptive containing a new progestogen, desogestrel, and 30 micrograms ethinylestradiol. Report on clinical studies from Scandinavia.
Acta Obstet Gynecol Scand Suppl; 1982; 111():1-60. PubMed ID: 6216716
[No Abstract] [Full Text] [Related]
17. [Hemostatic balance during treatment with the newest contraceptives].
Petersen KR; Skouby SO; Sidelmann J; Jespersen J
Ugeskr Laeger; 1994 Jan; 156(2):187-90. PubMed ID: 8296409
[TBL] [Abstract][Full Text] [Related]
18. Influence of modern low-dose oral contraceptives on hemostasis.
Daume E
Adv Contracept; 1990 Dec; 6 Suppl():51-67; discussion 68. PubMed ID: 2149806
[TBL] [Abstract][Full Text] [Related]
19. Hemostatic system changes induced by 50 micrograms and 30 micrograms estrogen/progestogen oral contraceptives. Modification of estrogen effects by levonorgestrel.
Sabra A; Bonnar J
J Reprod Med; 1983 Jan; 28(1 Suppl):85-91. PubMed ID: 6834350
[TBL] [Abstract][Full Text] [Related]
20. Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation.
Kemmeren JM; Algra A; Meijers JC; Bouma BN; Grobbee DE
Thromb Haemost; 2002 Feb; 87(2):199-205. PubMed ID: 11859850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
